What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 3
- “The purpose of this study is to deliver nimodipine via IV directly into the bloodstream and to determine if this is as safe and tolerable as oral nimodipine capsules.”In the company’s words, NCT05995405 on ClinicalTrials.gov
- Copy of
- Nimotop (Bayer Pharms)Tested side by side with the original in NCT05995405
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Dec 2024 | Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH | |
| Phase 1Completed | 17 Feb 2022 | Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026